baculovirus
insectspecif
pathogen
isol
speci
belong
order
lepidoptera
hymenoptera
diptera
orthoptera
coleoptera
neuroptera
thysaneura
trichoptera
taxonomi
baculovirida
famili
includ
four
genera
alphabaculoviru
nucleopolyhedrovirus
specif
lepidopteran
betabaculoviru
granulovirus
specif
lepidopteran
gammabaculoviru
nucleopolyhedrovirus
specif
hymenopteran
deltabaculoviru
granulovirus
specif
dipteran
jehl
et
al
herniou
et
al
virus
infect
arthropod
larva
possess
circular
doublestrand
deoxyribonucl
acid
dna
genom
rang
size
kbp
baculovir
genom
pack
insid
distinct
rodshap
nucleocapsid
nc
life
cycl
baculovirus
biphas
phase
character
differ
viral
phenotyp
environ
baculovirus
found
occlus
bodi
ob
protein
matrix
enclos
virion
provid
protect
harsh
environment
condit
temperatur
dehydr
ultraviolet
light
suscept
larva
ingest
ob
briefli
baculoviru
infect
cycl
insect
host
follow
ob
ingest
togeth
foliag
larva
dissolv
midgutreleas
occlusionderiv
virus
odv
damag
peritroph
membran
allow
receptormedi
endocytosi
odv
epitheli
cell
adam
mcclintock
odv
may
contain
one
multipl
rodshap
nc
depend
baculoviru
less
frequent
growth
condit
nc
enter
cytoplasm
transloc
nucleu
viral
dna
transcrib
replic
newli
synthes
genom
dna
assembl
specif
viral
protein
form
nc
nucleu
nc
travel
plasma
membran
bud
take
place
yield
bud
virus
bv
second
viral
phenotyp
respons
system
infect
larva
gene
express
tempor
regul
earli
gene
transcrib
directli
host
ribonucl
acid
rna
polymeras
ii
wherea
late
veryl
gene
transcript
depend
viral
rna
polymeras
late
gene
code
mostli
structur
protein
characterist
begin
system
infect
veryl
gene
code
odv
structur
protein
includ
major
ob
matrix
protein
horton
burand
haasstapleton
et
al
au
et
al
bv
infect
vivo
tissu
insect
cell
cultur
laakkonen
et
al
long
et
al
b
possibl
propag
virus
cell
cultur
made
baculovirus
access
tool
genet
engin
goodwin
et
al
studi
biolog
develop
recombin
protein
express
system
bev
baculoviru
express
vector
system
smith
et
al
system
consid
use
effici
robust
tool
mani
area
includ
limit
biotechnolog
clinic
biochemistri
molecular
biolog
fig
even
though
last
three
decad
differ
strategi
develop
gener
recombin
baculovirus
two
remain
wide
use
tradit
approach
consist
cotransfect
insect
cell
baculovir
genom
transfer
plasmid
transfer
plasmid
carri
gene
interest
flank
two
region
contain
sequenc
homolog
recombin
meanwhil
viral
genom
provid
genet
inform
wildtyp
viru
isol
recombin
event
made
select
obphenotyp
nonocclud
virus
observ
microscopi
howev
due
low
recombin
frequenc
rang
origin
techniqu
yield
high
proport
nonrecombin
wildtyp
viru
fig
oreilli
miller
contamin
parent
viru
make
isol
purif
recombin
virus
labori
sinc
involv
multipl
plaqu
figur
baculoviru
express
vector
system
bev
recombin
baculoviru
rbv
enter
cell
via
endocytosi
follow
event
nucleocapsid
nc
releas
cytoplasm
transloc
nucleu
viral
dna
express
simplifi
scheme
viral
dna
present
highlight
promot
code
sequenc
gene
interest
goi
altern
promot
immedi
earli
protein
polh
promot
baculoviru
genom
use
protein
express
insect
cell
promot
simian
viru
immedi
earli
protein
cytomegaloviru
cmv
elong
factor
ef
hybrid
cag
promot
human
ubiquitin
c
pol
iii
drosophila
melanogast
among
other
commonli
use
express
mammalian
cell
left
schemat
differ
applic
baculoviru
express
system
select
step
time
consum
order
reduc
parent
viru
progeni
baculovir
genom
linear
uniqu
restrict
site
accessori
gene
polh
code
major
protein
nucleopolyhedrovirus
ob
polyhedrin
polh
strong
baculovir
promot
high
express
insect
cell
sinc
linear
genom
replic
noninfect
genom
becom
circular
homolog
recombin
transfer
vector
abl
produc
progeni
modif
system
provid
recombin
frequenc
near
classic
methodolog
rbv
gener
homolog
recombin
baculovir
wildtyp
genom
transfer
plasmid
contain
gene
interest
goi
insect
cell
b
linear
viral
genom
approach
viral
genom
linear
essenti
gene
truncat
approach
facilit
recombin
viru
select
step
homolog
recombin
reconstitut
c
bactobac
transpositionbas
technolog
goi
insert
sitespecif
transposit
bacmid
insid
escherichia
coli
cell
flashbac
system
homolog
recombin
occur
bacmid
transfer
plasmid
insect
cell
bacteri
sequenc
elimin
recombin
event
possibl
isol
wildtyp
viru
still
exist
due
genet
repair
event
incomplet
digest
fig
posse
et
al
modif
made
system
insert
addit
uniqu
restrict
site
one
insert
essenti
gene
disrupt
linear
viral
dna
restrict
enzym
digest
open
read
frame
orf
code
phosphoprotein
key
compon
nc
delet
render
undesir
recircular
event
nonviabl
kitt
posse
second
wide
use
methodolog
sitespecif
transposit
transposon
bacmid
contain
baculovir
genom
fig
system
commerci
avail
bactobac
express
system
invitrogen
inc
shortli
techniqu
gener
recombin
baculovirus
consist
sitespecif
transposit
transfer
vector
pfastbac
carri
goi
strong
baculovir
promot
bacmid
bacmid
contain
site
bacteri
origin
replic
minif
propag
escherichia
coli
e
coli
strain
contain
helper
plasmid
code
transposas
bacmid
transfer
plasmid
transform
bacteria
contain
helper
plasmid
sitespecif
transposit
take
place
gener
recombin
baculovir
genom
select
clone
made
white
blue
coloni
screen
bacmid
purifi
bacteri
cultur
transfect
cell
insid
replic
thu
gener
recombin
baculovirus
downsid
system
develop
therapeut
product
veterinari
human
use
presenc
bacteri
genom
sequenc
select
marker
antibiot
resist
oxford
express
technolog
made
safer
approach
flashbac
platform
combin
two
wide
use
methodolog
gener
recombin
baculovirus
fig
platform
base
bacmid
essenti
gene
partial
delet
accessori
gene
also
knock
homolog
recombin
occur
insect
cell
transfer
plasmid
contain
part
restor
complet
sequenc
essenti
gene
elimin
bacteri
sequenc
je
et
al
hitchman
et
al
flashbac
platform
also
offer
variant
increas
yield
specif
target
protein
gold
ultra
prime
recent
new
platform
known
multibac
develop
geneva
biotech
express
multipl
polypeptid
especi
suitabl
product
eukaryot
multiprotein
complex
berger
et
al
system
allow
insert
foreign
gene
two
differ
loci
engin
baculovir
genom
polyhedrin
locu
chiavcath
locu
advantag
multibac
tandem
recombin
permit
express
protein
variou
subunit
reduct
proteolyt
activ
cell
express
system
product
therapeut
protein
establish
use
recombin
dna
technolog
mammalian
plant
insect
fungal
bacteri
cell
well
transgen
multicellular
organ
wu
et
al
steinbach
et
al
chen
et
al
katagiri
et
al
hammond
et
al
bev
divid
two
stage
first
gener
isol
recombin
baculoviru
carri
goi
second
infect
suscept
host
cultur
cell
larva
recombin
viru
oreilli
miller
first
recombin
protein
produc
use
bev
human
interferon
beta
smith
et
al
date
thousand
protein
express
use
system
far
wide
use
viru
autographa
californica
nucleopolyhedroviru
acmnpv
howev
bombyx
mori
nucleopolyhedroviru
also
use
due
higher
protein
express
use
silkworm
larva
pupa
motohashi
et
al
commonli
use
promot
express
heterolog
protein
bev
polh
promot
polh
promot
promot
high
express
capac
becom
activ
follow
late
stage
infect
term
cell
line
deriv
spodoptera
frugiperda
ovari
expresssf
trichoplusia
ni
highfiv
invitrogen
carlsbad
ca
unit
state
one
frequent
chosen
user
bev
line
abl
grow
adher
suspens
serumfre
media
without
requir
co
grace
granado
vaughn
et
al
lynn
ikonom
et
al
agatho
report
highfiv
cell
highest
heterolog
protein
express
yield
yamaji
et
al
larva
belong
order
lepidoptera
silkworm
also
use
express
similar
protein
yield
higher
rate
product
lower
cost
compar
cell
cultur
howev
requir
good
manufactur
practic
qualiti
control
use
larva
difficult
achiev
make
use
insect
common
although
insect
cell
line
secur
mammalian
one
screen
adventiti
agent
pose
risk
human
veterinari
health
alphanodaviru
rhabdoviru
isol
helicoverpa
armigera
frugiperda
cell
respect
bai
et
al
et
al
disadvantag
associ
use
cell
cultur
larva
first
round
infect
cell
lyse
entir
cultur
replac
allow
continu
express
goi
howev
use
lowcost
serumfre
media
somewhat
help
overcom
disadvantag
recombin
protein
product
also
improv
delet
baculovir
accessori
gene
chitinas
cathepsin
posit
effect
integr
intracellular
secret
recombin
protein
kaba
et
al
hitchman
et
al
mani
advantag
bev
express
system
provid
eukaryot
platform
adequ
fold
disulfid
bridg
establish
oligomer
posttransl
modif
need
biolog
activ
protein
moreov
high
protein
yield
obtain
use
strong
viral
promot
system
allow
simultan
express
multipl
gene
due
baculovir
genom
capac
insert
dna
fragment
kbp
oreilli
et
al
import
mention
product
recombin
protein
use
system
great
scaleup
potenti
lowassoci
cost
low
biosecur
requir
need
sinc
baculovirus
limit
host
rang
nonpathogen
human
term
posttransl
modif
recombin
protein
eukaryot
glycosyl
bev
present
simpl
protein
glycosyl
pattern
howev
nglycosyl
protein
insect
cell
resembl
fulli
mammalian
cell
cultur
insect
nglycan
termin
mannos
residu
mammalian
nglycan
often
termin
sialic
acid
residu
differ
may
result
lower
even
total
loss
biolog
function
protein
interest
jarvi
order
overcom
problem
human
insect
cell
develop
express
mammalian
glycosyl
enzym
harrison
jarvi
jarvi
et
al
mabashiasazuma
et
al
okada
et
al
anoth
strategi
consist
modifi
baculovir
genom
order
express
goi
along
glycosyl
enzym
sweetbac
palmberg
et
al
product
contamin
baculovirus
might
problem
use
bev
develop
human
veterinari
vaccin
marek
et
al
develop
system
call
bacfre
methodolog
use
defici
baculoviru
propag
cell
provid
tran
delet
essenti
gene
prevent
assembl
viral
phenotyp
bv
odv
marek
et
al
rapid
scalabl
lowcost
product
use
technolog
particularli
import
term
confront
sanitari
emerg
influenza
pandem
fedson
dunnil
report
global
bioreactor
capac
use
gener
antiflu
vaccin
bev
million
vial
could
produc
month
oppos
classic
platform
use
purpos
involv
embryon
chicken
egg
take
month
wong
webbi
mean
nowaday
product
influenza
vaccin
begin
month
exact
preval
strain
influenza
know
certain
bev
platform
use
instead
time
requir
product
would
day
cox
last
year
scientif
commun
use
platform
product
recombin
protein
laboratori
scale
howev
last
decad
bev
start
gain
prioriti
biotechnolog
industri
date
five
veterinari
vaccin
four
product
human
use
exist
market
includ
vaccin
immunotherapi
gene
therapi
vector
tabl
flublok
first
recombin
vaccin
licens
us
food
drug
administr
prevent
season
influenza
manufactur
use
bev
expressf
insect
cell
trival
recombin
hemagglutinin
ha
vaccin
produc
protein
scienc
corpor
contain
ha
antigen
deriv
three
influenza
viru
strain
select
inclus
annual
influenza
vaccin
world
health
organ
updat
annual
basi
holtz
et
al
wang
et
al
sinc
system
replic
subsequ
inactiv
step
live
influenza
viru
crucial
licens
eggbas
vaccin
need
use
altern
diamyd
therapeut
vaccin
produc
use
bev
cell
aim
treat
type
diabet
diamyd
recombin
kda
glutam
decarboxylas
correspond
human
glutam
decarboxylas
major
autoantigen
type
diabet
diamyd
develop
diamyd
medic
produc
protein
scienc
corpor
hink
summari
bev
valuabl
platform
manufactur
great
varieti
biotechnolog
product
sinc
one
insect
cell
line
singl
method
construct
recombin
baculovirus
possibl
express
larg
varieti
product
baculovirusinsect
cell
express
system
wide
use
gener
antigen
develop
viral
vaccin
human
veterinari
use
cox
mena
kamen
van
oer
yamaji
classic
viral
vaccin
firstgener
vaccin
measl
rubella
rabi
yellow
fever
use
attenu
viral
strain
inactiv
virus
attenu
correspond
limit
viral
replic
vaccin
although
immun
respons
induc
kind
vaccin
similar
natur
infect
advers
reaction
dismiss
convers
inactiv
strain
replic
sinc
genet
materi
destroy
make
secur
attenu
one
howev
immun
respons
gener
formul
effici
three
five
dose
gener
requir
attain
optim
antibodi
titer
addit
risk
incomplet
inactiv
lead
event
cutter
incid
polio
case
caus
defect
polio
vaccin
unit
state
fitzpatrick
altern
set
outclass
type
vaccin
consist
subunit
recombin
protein
formul
includ
viruslik
particl
vlp
recombin
vaccin
carri
limit
number
viral
protein
either
complet
truncat
nonpathogen
viral
vector
vlp
selfassembl
complex
protein
structur
resembl
wildtyp
viral
capsid
envelop
virion
differ
latter
vlp
contain
pathogen
replic
genom
vaccin
formul
structur
combin
advantag
attenu
vaccin
subunit
vaccin
sinc
epitop
recogn
host
immun
system
effici
stimul
adapt
immun
respons
avoid
possibl
revers
virul
phenotyp
vlp
classifi
two
type
base
structur
envelop
vlp
includ
hostderiv
lipid
membran
nake
nonenvelop
simpli
refer
vlp
likewis
also
classifi
simpl
multipl
vlp
depend
number
differ
recombin
protein
includ
structur
noad
roy
et
al
difficulti
may
associ
vlp
product
exampl
protein
stoichiometri
problem
sinc
incorpor
adequ
proport
protein
may
occur
latham
galarza
howev
even
vlp
fulli
resembl
wildtyp
viru
stimul
host
immun
system
extent
high
enough
meet
requir
vaccin
candid
vlp
repres
signific
advanc
term
develop
prevent
tool
virus
propag
cell
line
ex
vivo
cultur
hepat
b
viru
enter
adenovirus
type
vlp
product
use
bev
accomplish
one
two
altern
combin
first
consist
coinfect
insect
cell
mani
recombin
virus
protein
manufactur
want
assembl
vlp
structur
monocistron
baculovirus
singl
polycistron
viru
code
protein
complex
multiprotein
vlp
present
difficulti
product
sinc
infect
multipl
recombin
baculovirus
homogen
vieiria
et
al
compar
strategi
product
rotaviru
vlp
contain
observ
coexpress
strategi
superior
coinfect
one
meanwhil
et
al
vlp
found
opposit
vieira
et
al
et
al
day
vast
array
taxonom
structur
differ
vlp
produc
use
bev
mani
alreadi
preclin
clinic
trial
stage
seven
vlpbase
vaccin
alreadi
approv
current
commerci
tabl
one
promis
product
alreadi
market
cervarix
vlpbase
vaccin
human
papillomavirus
respons
cervic
cancer
case
produc
glaxosmithklin
oz
et
al
smith
et
al
mention
earlier
bev
use
produc
substanti
amount
heterolog
protein
use
immunogen
strategi
although
key
subunit
vaccin
develop
replac
peptid
display
virion
surfac
baculoviru
surfac
display
refer
display
heterolog
peptid
protein
surfac
bv
differ
strategi
involv
translat
fusion
peptid
portion
kost
et
al
xu
et
al
major
surfac
protein
class
iii
integr
membran
glycoprotein
bud
virion
abl
mediat
membran
fusion
acid
ph
condit
acmnpv
acid
long
phosphoglycoprotein
cystein
residu
particip
disulfid
bridg
format
requir
stabil
biolog
activ
hefferon
et
al
garri
garri
surfac
display
heterolog
polypeptid
achiev
construct
chimera
complet
wildtyp
transmembran
multimer
carboxytermin
cytoplasm
tail
domain
target
protein
express
recombin
fuse
short
long
heterolog
peptid
grabherr
ernst
baculoviru
display
heterolog
protein
fusion
demonstr
effect
immunogen
success
abl
induc
antibodi
respons
varieti
display
protein
kost
et
al
addit
baculovirus
abl
trigger
robust
innat
immun
respons
activ
profession
antigenpres
cell
baculovirus
display
heterolog
envelop
protein
vesicular
stomat
viru
vsv
g
protein
also
construct
sever
studi
shown
vsvg
capabl
improv
transduct
effici
baculoviru
vertebr
cell
barsoum
et
al
differ
strategi
develop
increas
effect
viru
display
chappl
jone
polypeptid
display
vsvg
exhibit
higher
densiti
recombin
protein
fusion
protein
homogen
distribut
bv
compar
mostli
apic
contrast
surfac
display
heterolog
protein
display
nc
virion
nc
core
compos
circular
coval
close
dsdna
genom
major
basic
core
protein
nc
sheath
form
stack
ringlik
subunit
consist
one
major
polypeptid
sever
minor
protein
nc
display
strategi
involv
translat
fusion
peptid
kukkonen
et
al
molinari
et
al
pidr
et
al
depend
host
immun
respons
target
one
strategi
might
chosen
antigen
display
nc
abl
reach
cytosol
preferenti
trigger
major
histocompat
complex
class
present
pathway
mount
strong
tcell
respons
molinari
et
al
turn
bv
display
antigen
surfac
elicit
humor
respons
gronowski
et
al
abe
et
al
sever
studi
shown
baculoviru
display
gener
high
titer
specif
antibodi
protect
differ
pathogen
japanes
enceph
viru
avian
reoviru
human
enteroviru
influenza
malaria
xu
et
al
lin
et
al
marek
et
al
jin
et
al
madhan
et
al
adenoassoci
virus
aav
becom
relev
vivo
genetherapi
nayerossadat
et
al
flott
wang
gao
therapi
involv
incorpor
gene
cell
aav
use
viral
vector
tool
allow
safe
effici
specif
incorpor
gene
insid
organ
first
group
hereditari
diseas
genetherapi
investig
includ
hemophilia
b
leber
macular
degener
duchenn
muscular
dystrophi
nowaday
mani
studi
focus
central
nervou
system
diseas
parkinson
differ
type
cancer
cardiovascular
afflict
bone
regener
flott
et
al
kay
et
al
kaplitt
et
al
jiang
et
al
estim
human
popul
expos
least
one
event
infect
aav
advers
consequ
associ
infect
latenc
virus
boutin
et
al
erl
et
al
tobiasch
et
al
aav
singlestrand
dna
genom
nonenvelop
virus
nm
diamet
belong
parvoviru
famili
classifi
member
dependoviru
genu
twenti
human
nonhuman
primat
strain
isol
serotyp
except
serotyp
share
similar
capsid
structur
genom
size
organ
aav
genom
size
approxim
kb
contain
two
orf
code
four
regulatori
protein
orf
flank
two
invert
termin
repeat
itr
contain
cisregulatori
sequenc
need
viral
infect
major
protein
involv
genom
excis
rescu
replic
integr
integr
host
genom
sitespecif
take
place
chromosom
specif
locu
human
genom
without
advers
consequ
minor
protein
respons
accumul
dna
packag
structur
protein
encod
cap
orf
recombin
aav
construct
replac
rep
cap
gene
goi
flank
itr
region
viral
vector
abl
transduc
activ
divis
quiescent
cell
import
highlight
contrast
wt
aav
recombin
aav
sitespecif
integr
capac
sinc
rep
gene
absent
thu
integr
occur
random
howev
estim
integr
frequenc
recombin
adenoassoci
virus
raav
mammalian
cell
line
mccarti
et
al
view
establish
stabl
persist
express
patient
altern
genom
integr
develop
consist
doublestrand
dna
persist
episom
insid
cell
yang
et
al
date
adenoassoci
vector
modifi
tissuespecif
prefer
organ
immuneprivileg
eye
brain
classic
techniqu
product
aav
involv
hela
cell
cotransfect
two
plasmid
one
contain
recombin
dna
recombin
adenoassoci
viru
plasmid
rep
cap
gene
phelper
cell
infect
helper
viru
adenoviru
herp
simplex
viru
allow
replic
recombin
aav
samulski
et
al
downsid
methodolog
possibl
undesir
recombin
event
plasmid
purif
helper
viru
time
consum
scaleup
process
difficult
achiev
good
altern
use
bev
platform
revis
galibert
merten
involv
use
three
recombin
baculovirus
cell
three
recombin
baculovirus
contain
one
follow
gene
rep
cap
construct
interest
flank
itr
altern
involv
polycistron
baculoviru
contain
rep
cap
gene
also
use
smith
et
al
onebac
system
involv
transgen
insect
cell
line
express
gene
rep
cap
aav
one
recombin
baculoviru
effici
techniqu
scaleup
feasibl
higher
previou
altern
provid
flexibl
strategi
sinc
allow
product
aav
serotyp
simpli
chang
cell
line
mietzsch
product
deriv
bev
contamin
raav
baculoviru
particl
reduc
alreadi
one
raav
produc
bev
market
commerci
glybera
alipogen
tiparvovec
develop
market
uniqur
compens
lipoprotein
lipas
defici
receiv
regulatori
approv
european
medicin
agenc
although
discontinu
due
lack
demand
demonstr
baculovir
genom
capabl
transduc
mammalian
cell
heterolog
gene
control
adequ
mammalian
promot
orf
carri
baculovir
genom
transient
express
cell
viral
promot
simian
virus
immedi
earli
protein
cmv
elong
hybrid
cag
promot
human
ubiquitin
c
pol
iii
drosophila
melanogast
among
other
commonli
use
express
mammalian
cell
follow
first
day
baculovir
genom
degrad
unabl
insert
mammalian
genom
absenc
select
pressur
volkman
goldsmith
carbonel
et
al
boyc
bucher
present
baculovir
transduct
abil
document
vitro
vivo
varieti
cell
type
includ
embryon
stem
cell
pluripot
stem
cell
kost
et
al
ho
et
al
airenn
et
al
chen
et
al
suggest
mechan
baculovirus
ingress
mammalian
cell
clathrin
dynamindepend
endocytosi
macropinocytosi
makkonen
show
process
also
requir
host
cell
protein
heparan
sulfat
proteoglycan
serv
receptor
long
et
al
b
kataoka
et
al
makkonen
et
al
makkonen
et
al
nasimuzzaman
insid
cell
baculoviru
virion
transport
endosom
acid
condit
promot
membran
fusion
mediat
genet
materi
thu
liber
cytoplasm
actin
cytoskeleton
reorgan
promot
transloc
baculovir
genom
nucleu
transcript
occur
host
machineri
one
advantag
use
baculoviru
vector
mammalian
cell
transduct
contrast
virus
use
end
human
pathogen
replic
mammalian
cell
integr
genom
document
preexist
immun
baculovirus
strauss
et
al
jin
et
al
human
studi
made
volunt
consum
ob
diet
result
promis
sinc
inflammatori
respons
allergi
advers
effect
observ
followup
heimpel
et
al
studi
extend
anim
model
evalu
possibl
sideeffect
skin
irrit
cytotox
neg
kost
condreay
jin
et
al
even
though
downsid
use
baculoviru
viral
vector
gene
deliveri
lack
longterm
express
transgen
altern
overcom
develop
exampl
lo
et
al
engin
baculoviru
vector
system
creloxp
site
approach
construct
excis
remain
episom
cell
prolong
express
lo
et
al
evid
togeth
fact
baculovirus
infect
organ
besid
phylum
arthropoda
show
safe
vector
develop
dna
vaccin
immunotherapi
gene
therapi
reflect
increas
number
peerreview
public
use
recombin
baculovirus
viral
vector
exampl
swift
et
al
use
baculoviru
prodrug
approach
mediat
celldeath
prostat
cancer
cell
success
even
observ
good
capac
celllay
penetr
compar
viral
vector
last
year
gene
silenc
rna
interfer
becom
relev
gene
regul
baculovir
vector
engin
deliv
microribonucl
acid
short
hairpin
ribonucl
acid
insect
mammalian
cell
success
gottardo
pidr
show
baculovirusmedi
gene
silenc
human
increas
surviv
reduc
progress
pituitari
tumor
growth
vivo
gottardo
et
al
type
strategi
also
appli
interfer
viral
pathogen
infect
human
anim
makkonen
et
al
year
baculovirus
exploit
molecular
biolog
laboratori
trend
never
stop
increas
sinc
highli
versatil
tool
lowassoci
cost
scalabl
product
pharmaceut
giant
merck
take
advantag
baculovirus
mere
biolog
control
agent
anymor
also
key
state
art
genetherapi
immun
depart
one
relev
advantag
bev
rapid
respons
epidemiolog
emerg
influenza
pandem
meanwhil
classic
firstgener
eggbas
approach
develop
flu
vaccin
nonsuit
allerg
user
take
six
month
develop
bev
recombin
technolog
approach
give
fulli
function
vaccin
within
first
day
outbreak
use
bev
inexpens
direct
also
provid
uniqu
plastic
togeth
fact
almost
special
biosafeti
measur
taken
account
applic
make
excel
platform
compar
system
